CuraGen’s Board Agrees To Two-for-One Stock Split

Mar 09, 2000

Premium

NEW HAVEN, Conn.--CuraGen announced that its Board of Directors has approved a two-for-one stock split of the company’s common stock on March 30. At that time, stockholders will receive one additional share of the stock for every share each owned at the close of business on March 15. The stock will begin trading on a split-adjusted basis on March 31.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

When the Ailment You're Studying Becomes Personal

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

Irish Genomics Initiative Looks to Expand Into Scotland

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

Another Source of Data for 23andMe

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

This Week in PLOS

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Main menu